Deutsche Bank Reiterates a 'Hold' on Chelsea Therapeutics (CHTP); Saga With FDA Takes New Turn
Tweet
Share
E-mailGet Alerts CHTP Hot Sheet
Price: $6.52 --0%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Deutsche Bank reiterates a 'Hold' on Chelsea Therapeutics (NASDAQ: CHTP).
Deutsche analyst said, "FDA is concerned that the suggested trial amendments to Study 306B, which is evaluating Northera vs. placebo in NOH patients, were based on Chelsea having unblinded the trial. In speaking with Chelsea, this is not the case and the trial remains blinded. The FDA is taking a theoretical approach that Chelsea may have received hints of data from its CRO that would allow it to design the trial to work. The FDA has stated that Chelsea's 306b would not be adequate for approval due to this theoretical risk."
Overall, the Deutsche analyst would feel more comfortable if a trial on the higher-end or longer than 3 months was implemented
For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.
Shares of Chelsea Therapeutics closed at $1.46 yesterday.
Deutsche analyst said, "FDA is concerned that the suggested trial amendments to Study 306B, which is evaluating Northera vs. placebo in NOH patients, were based on Chelsea having unblinded the trial. In speaking with Chelsea, this is not the case and the trial remains blinded. The FDA is taking a theoretical approach that Chelsea may have received hints of data from its CRO that would allow it to design the trial to work. The FDA has stated that Chelsea's 306b would not be adequate for approval due to this theoretical risk."
Overall, the Deutsche analyst would feel more comfortable if a trial on the higher-end or longer than 3 months was implemented
For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.
Shares of Chelsea Therapeutics closed at $1.46 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
